Insider Transactions in Q1 2024 at Laboratory Corp Of America Holdings (LH)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,553
-31.75%
|
$767,448
$216.74 P/Share
|
|
Mar 27
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,605
-18.89%
|
$562,680
$216.57 P/Share
|
|
Mar 27
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,158
+30.86%
|
-
|
|
Mar 27
2024
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,061
-15.36%
|
$1,093,176
$216.57 P/Share
|
|
Mar 27
2024
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,556
+25.97%
|
-
|
|
Mar 27
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,079
-30.61%
|
$1,097,064
$216.57 P/Share
|
|
Mar 27
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,556
+41.05%
|
-
|
|
Mar 27
2024
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
31,799
-25.35%
|
$6,868,584
$216.57 P/Share
|
|
Mar 27
2024
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
72,435
+36.61%
|
-
|
|
Mar 27
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Payment of exercise price or tax liability
|
Direct |
952
-14.85%
|
$205,632
$216.57 P/Share
|
|
Mar 27
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
BUY
Exercise of conversion of derivative security
|
Direct |
3,012
+31.96%
|
-
|
|
Mar 27
2024
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
894
-16.49%
|
$193,104
$216.57 P/Share
|
|
Mar 27
2024
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,079
+36.23%
|
-
|
|
Mar 27
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,162
-22.43%
|
$466,992
$216.57 P/Share
|
|
Mar 27
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,778
+37.48%
|
-
|
|
Mar 27
2024
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,805
-20.18%
|
$1,901,880
$216.57 P/Share
|
|
Mar 27
2024
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
20,033
+31.47%
|
-
|
|
Mar 27
2024
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,299
-10.54%
|
$712,584
$216.57 P/Share
|
|
Mar 27
2024
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,697
+19.73%
|
-
|
|
Mar 07
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
227
-5.56%
|
$49,486
$218.45 P/Share
|
|
Mar 07
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
5,048
-50.06%
|
$1,100,464
$218.45 P/Share
|
|
Mar 07
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,119
+17.36%
|
$247,923
$117.09 P/Share
|
|
Feb 21
2024
|
Glenn A Eisenberg Executive Vice President |
SELL
Open market or private sale
|
Direct |
34,504
-19.67%
|
$7,452,864
$216.64 P/Share
|
|
Feb 21
2024
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
14,054
+19.48%
|
$2,290,802
$163.63 P/Share
|
|
Feb 21
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Open market or private sale
|
Direct |
500
-12.82%
|
$107,500
$215.49 P/Share
|
|
Feb 13
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
237
-3.01%
|
$53,562
$226.45 P/Share
|
|
Feb 12
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Payment of exercise price or tax liability
|
Direct |
59
-1.49%
|
$13,393
$227.45 P/Share
|
|
Feb 12
2024
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
215
-0.49%
|
$48,805
$227.45 P/Share
|
|
Feb 12
2024
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,231
-2.27%
|
$279,437
$227.45 P/Share
|
|
Feb 12
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
66
-1.59%
|
$14,982
$227.45 P/Share
|
|
Feb 12
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
126
-1.56%
|
$28,602
$227.45 P/Share
|
|
Feb 12
2024
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
87
-0.37%
|
$19,749
$227.45 P/Share
|
|
Feb 12
2024
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
137
-0.64%
|
$31,099
$227.45 P/Share
|
|
Feb 12
2024
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
43
-1.8%
|
$9,761
$227.45 P/Share
|
|
Feb 12
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
87
-1.09%
|
$19,749
$227.45 P/Share
|
|
Feb 11
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
BUY
Exercise of conversion of derivative security
|
Direct |
201
+4.83%
|
-
|
|
Feb 11
2024
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
807
+1.79%
|
-
|
|
Feb 11
2024
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,964
+5.18%
|
-
|
|
Feb 11
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
201
+4.62%
|
-
|
|
Feb 11
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
472
+5.51%
|
-
|
|
Feb 11
2024
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
324
+1.35%
|
-
|
|
Feb 11
2024
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
472
+2.15%
|
-
|
|
Feb 11
2024
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
123
+4.91%
|
-
|
|
Feb 11
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
324
+3.91%
|
-
|
|
Feb 08
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
259
-3.28%
|
$57,498
$222.06 P/Share
|
|
Feb 07
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Payment of exercise price or tax liability
|
Direct |
119
-1.58%
|
$26,537
$223.71 P/Share
|
|
Feb 07
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
BUY
Exercise of conversion of derivative security
|
Direct |
362
+4.58%
|
-
|
|
Feb 07
2024
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
236
-0.54%
|
$52,628
$223.71 P/Share
|
|
Feb 07
2024
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
885
+1.99%
|
-
|
|
Feb 07
2024
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,149
-2.19%
|
$256,227
$223.71 P/Share
|